|Day Low/High||62.31 / 63.30|
|52 Wk Low/High||53.63 / 71.70|
Markets have certainly recovered nicely off of the lows of late September. Now, here in mid-October, it feels like it did that cold night back in 1980-something. The wolves are visible and noisy.
Investors are chasing every name that's developing a promising coronavirus vaccine. These stocks will be winners no matter which companies are successful.
Covid itself, and therapeutics or vaccines associated with taking on the SARS-CoV-2 coronavirus, is under a public microscope.
Now, that we have confirmation from the Nasdaq Composite, I think we can say equity markets are indeed back in what I would consider an uptrend.
Even more important than fiscal support moving forward would be the concept of Covid-19 very soon being effectively treatable for the public.
The result has been a technical breakdown in risk-asset pricing -- and the main culprit is without a doubt, the inability of Congress to compromise.
RedHill Biopharma has adopted 'Veeva Vault CDMS', Veeva's modern cloud platform.
Make sure that your portfolio is composed of sane assets for the balance of this crazy year.
Electoral risk remains the monster under the bed, and it only grows as our legislators intentionally choose the blame game over honest cooperation.
The prices of hotels and even beaten up retailers say that many believe a vaccine is on the way -- here's how I would get positioned.
I am long Merck, not Seattle Genetics, though the one to own now is obviously SGEN.
Also, several scheduled events this week, election risk, earnings to watch.
After reviewing the rally, let's zero in on one biotech name, Genprex, and where it appears to be going.
This writer is rooting for the success of all efforts to halt the spread of the virus as he struggles with the aftereffects of the disease.
* On counter punching * And being opportunistic, flexible and unemotional As you all recognize I work off an investment thesis, the foundation of which typically is the relationship of a stock, a sector or an Index to my calculation of "fair market ...
We must see equity markets, the Nasdaq Composite and Nasdaq 100 in particular, fight back this week to keep on believing in this market.
"Just one more thing." - Lt. Columbo Statnews.com is reporting that the phase 3 study for AstraZeneca's Covid-19 vaccine is put on hold.
An effective Covid-19 will be a game-changer, but charts say the bottom-line impact may not be as significant as previously believed.
Plus, reading tea leaves in the recent action in Apple and Salesforce.com.
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
Monday's market action was in no way similar to that recent disparity between the 'haves' and 'have nots.'
The equity market recovery is just as sloppy in performance as the economy itself.
It is going to take successful vaccines and therapies and much lower unemployment to revive most of Walt Disney Co.'s businesses.
European markets have been slumping for years, but the time for those countries to shine again may finally be around the corner.
Plus, Russia could provide a real-time clinical trial of a coronavirus vaccine.
The Fed has done a lot, and is willing to do even more, but for now, is watching Congress. The fiscal side is where the next shoe falls.
Let me disabuse you of some of the biggest canards that people routinely spout involving the Fed and stocks.
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.
You can bet on black, which is instant vaccine, or you can bet on red, which is the shutdown non-economy. Both have variants.
Oxford University, along with Britain's AstraZeneca, published promising data from an early stage trial of a key coronavirus vaccine study Monday in London.